Reata Pharmaceuticals Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
323
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.61B
Reata Pharmaceuticals General Information
Description
Developer of oral anti-inflammatory drugs intended for the treatment of serious and life-threatening diseases. The company focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways.
Contact Information
Website
www.reatapharma.comCorporate Office
- 5320 Legacy Drive
- Plano, TX 75024
- United States
Corporate Office
- 5320 Legacy Drive
- Plano, TX 75024
- United States
Reata Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Merger/Acquisition | 26-Sep-2023 | $6.61B | Completed | Generating Revenue | ||
| 14. Debt - General | 01-May-2023 | Completed | Generating Revenue | |||
| 13. PIPE | 24-Jun-2020 | Completed | Generating Revenue | |||
| 12. 2PO | 14-Nov-2019 | Completed | Generating Revenue | |||
| 11. 2PO | 06-Dec-2016 | Cancelled | Generating Revenue | |||
| 10. Debt - General | 03-Apr-2017 | Completed | Generating Revenue | |||
| 9. IPO | 26-May-2016 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series H) | 13-Jul-2011 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series G) | 28-Sep-2009 | $78M | $176M | Completed | Generating Revenue | |
| 6. Later Stage VC (Series F) | 04-Dec-2008 | $32M | $98.4M | Completed | Generating Revenue |
Reata Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series H | ||||||||
| Series G2 | ||||||||
| Series G1 | ||||||||
| Series F | ||||||||
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 3,331,247 | $0.001000 | $0.12 | $1.5 | $1.5 | 1x | $1.5 | 3.4% |
| Series A | 1,751,000 | $0.001000 | $0.08 | $1 | $1 | 1x | $1 | 1.79% |
Reata Pharmaceuticals Comparisons
Industry
Financing
Details
Reata Pharmaceuticals Competitors (76)
One of Reata Pharmaceuticals’s 76 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA | ||||
| etherna | Formerly VC-backed | Niel, Belgium | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA |
Reata Pharmaceuticals Patents
Reata Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022208727-A1 | Synthetic ursolic acid derivatives and methods of use thereof | Inactive | 18-Jan-2021 | ||
| CA-3204434-A1 | Synthetic ursolic acid derivatives and methods of use thereof | Pending | 18-Jan-2021 | ||
| EP-4277916-A1 | Synthetic ursolic acid derivatives and methods of use thereof | Pending | 18-Jan-2021 | ||
| US-20240140986-A1 | Synthetic ursolic acid derivatives and methods of use thereof | Pending | 18-Jan-2021 | ||
| WO-2022155614-A1 | Synthetic ursolic acid derivatives and methods of use thereof | Inactive | 18-Jan-2021 | C07J63/008 |
Reata Pharmaceuticals Signals
Reata Pharmaceuticals Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie | Corporation | Majority | ||
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Blackstone | PE/Buyout | Minority | ||
| Blackstone Life Sciences | Other Private Equity | Minority | ||
| CIC Partners | PE/Buyout | Minority |
Reata Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated December, 31, 2023
25.99 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Reata Pharmaceuticals Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Reata Pharmaceuticals Global | Cambridge, MA | 2020 | |
| Reata Pharmaceuticals Holdings | Plano, TX |
Reata Pharmaceuticals FAQs
-
When was Reata Pharmaceuticals founded?
Reata Pharmaceuticals was founded in 2002.
-
Where is Reata Pharmaceuticals headquartered?
Reata Pharmaceuticals is headquartered in Plano, TX.
-
What is the size of Reata Pharmaceuticals?
Reata Pharmaceuticals has 323 total employees.
-
What industry is Reata Pharmaceuticals in?
Reata Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Reata Pharmaceuticals a private or public company?
Reata Pharmaceuticals is a Private company.
-
What is the current valuation of Reata Pharmaceuticals?
The current valuation of Reata Pharmaceuticals is .
-
What is Reata Pharmaceuticals’s current revenue?
The current revenue for Reata Pharmaceuticals is .
-
How much funding has Reata Pharmaceuticals raised over time?
Reata Pharmaceuticals has raised $1.64B.
-
Who are Reata Pharmaceuticals’s investors?
AbbVie, AbbVie Ventures, Blackstone, Blackstone Life Sciences, and CIC Partners are 5 of 16 investors who have invested in Reata Pharmaceuticals.
-
Who are Reata Pharmaceuticals’s competitors?
Crinetics Pharmaceuticals, Sarepta Therapeutics, Pharmacyclics, etherna, and Intellia Therapeutics are some of the 76 competitors of Reata Pharmaceuticals.
-
When was Reata Pharmaceuticals acquired?
Reata Pharmaceuticals was acquired on 26-Sep-2023.
-
Who acquired Reata Pharmaceuticals?
Reata Pharmaceuticals was acquired by Biogen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process